Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Armstrong

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
Annals of Epidemiology|April 11, 2019
Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: a cautionary taleHeather Bradley, Vicki Hogan, Christine Agnew-Brune, et al.
BMC Biology|October 11, 2007
Broadening the horizon--level 2.5 of the HUPO-PSI format for molecular interactionsSamuel Kerrien, Sandra Orchard, Luisa Montecchi-Palazzi, et al.
MMWR. Morbidity and Mortality Weekly Report|March 2, 2018
Notes from the Field: HIV Infection Investigation in a Rural Area - West Virginia, 2017Mary E Evans, Sarah M Labuda, Vicki Hogan, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
BMC Cancer|February 3, 2024
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMETRobert Olson, Hadassah Abraham, Curtis Leclerc, et al.
Nature Biotechnology|August 10, 2007
The minimum information required for reporting a molecular interaction experiment (MIMIx)Sandra Orchard, Lukasz Salwinski, Samuel Kerrien, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
Annals of Epidemiology|April 11, 2019
Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: a cautionary taleHeather Bradley, Vicki Hogan, Christine Agnew-Brune, et al.
BMC Biology|October 11, 2007
Broadening the horizon--level 2.5 of the HUPO-PSI format for molecular interactionsSamuel Kerrien, Sandra Orchard, Luisa Montecchi-Palazzi, et al.
MMWR. Morbidity and Mortality Weekly Report|March 2, 2018
Notes from the Field: HIV Infection Investigation in a Rural Area - West Virginia, 2017Mary E Evans, Sarah M Labuda, Vicki Hogan, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
BMC Cancer|February 3, 2024
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMETRobert Olson, Hadassah Abraham, Curtis Leclerc, et al.
Nature Biotechnology|August 10, 2007
The minimum information required for reporting a molecular interaction experiment (MIMIx)Sandra Orchard, Lukasz Salwinski, Samuel Kerrien, et al.
Pageof 9